Why the study?
SGLT2 inhibitors and GLP1-RA have cardio-kidney-metabolic benefit, but their prescription prevalence among T2DM patients with and without CKD in Australian primary care was not well understood.
Prescription rates for SGLT2 inhibitors and GLP1-RAs remain low in Australian primary care among patients with T2DM, even in those with CKD, indicating a need for strategies to improve guideline-directed therapy.
Answers are grounded in this paper and cite their sources.
Low rates of SGLT2 inhibitor and GLP-1 RA prescribing persist in T2DM with or without CKD; leaves open implementation barriers in Australian primary care.
AIMS: Sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have cardio-kidney-metabolic benefit. This study aimed to understand the prevalence of prescription of SGLT2 inhibitors and GLP1-RA among patients with T2DM with and without chronic kidney disease (CKD) in Australian primary care. MATERIALS AND METHODS: and UACR >11.3 to <565 mg/mmol). RESULTS: Of 114 499 adults with T2DM, 36 840 (32.1%) also had CKD. SGLT2 inhibitors were prescribed in 13.6% of patients without CKD, 14.4% of patients with CKD and 17.8% of patients meeting the trial target population definition. Across these groups, GLP1-RA were prescribed in 8.8%, 10.1% and 11.3% of patients, respectively. More advanced CKD stage and severely increased albuminuria were associated with a lower likelihood of SGLT2 inhibitor or GLP1-RA being prescribed. CONCLUSION: We observed low rates of SGLT2 inhibitor and GLP1-RA prescriptions in patients with T2DM irrespective of CKD status. Strategies are needed to improve prescription rates, with a particular focus on patients with high kidney and cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Wallace et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: